The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress

Genitourinary Cancers MORE >>

Among men in the ongoing phase II TRITON2 trial with BRCA1/2 alterations, 51% had a confirmed prostate-specific antigen response to rucaparib (Rubraca), according to preliminary data reported in a poster presentation by Wassim Abida, MD, PhD, and colleagues at the 2018 ESMO Congress.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.